Clinical Advances in Hematology and Oncology This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Management of < em > KRAS < /em > -mutated non-small cell lung cancer
Clin Adv Hematol Oncol. 2024 Mar;22(2):67-75.ABSTRACTKirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non-small cell lung cancer (NSCLC), where mutations are present in 32% of lung adenocarcinoma and 4% of squamous cell lung cancer. The most common KRAS variant is KRAS G12C, which accounts for nearly 40% of all KRAS mutations. Although it is the most common oncogenic driver in NSCLC, KRAS was considered a "nondruggable target" until recently, owing to the lack of any progress in developing targeted therapies for this oncogene. With the recent development and approva...
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Jyoti Malhotra Danny Nguyen Tingting Tan George B Semeniuk Iii Source Type: research

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

Management of < em > KRAS < /em > -mutated non-small cell lung cancer
Clin Adv Hematol Oncol. 2024 Mar;22(2):67-75.ABSTRACTKirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non-small cell lung cancer (NSCLC), where mutations are present in 32% of lung adenocarcinoma and 4% of squamous cell lung cancer. The most common KRAS variant is KRAS G12C, which accounts for nearly 40% of all KRAS mutations. Although it is the most common oncogenic driver in NSCLC, KRAS was considered a "nondruggable target" until recently, owing to the lack of any progress in developing targeted therapies for this oncogene. With the recent development and approva...
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Jyoti Malhotra Danny Nguyen Tingting Tan George B Semeniuk Iii Source Type: research

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

Management of < em > KRAS < /em > -mutated non-small cell lung cancer
Clin Adv Hematol Oncol. 2024 Mar;22(2):67-75.ABSTRACTKirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non-small cell lung cancer (NSCLC), where mutations are present in 32% of lung adenocarcinoma and 4% of squamous cell lung cancer. The most common KRAS variant is KRAS G12C, which accounts for nearly 40% of all KRAS mutations. Although it is the most common oncogenic driver in NSCLC, KRAS was considered a "nondruggable target" until recently, owing to the lack of any progress in developing targeted therapies for this oncogene. With the recent development and approva...
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Jyoti Malhotra Danny Nguyen Tingting Tan George B Semeniuk Iii Source Type: research

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

Management of < em > KRAS < /em > -mutated non-small cell lung cancer
Clin Adv Hematol Oncol. 2024 Mar;22(2):67-75.ABSTRACTKirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non-small cell lung cancer (NSCLC), where mutations are present in 32% of lung adenocarcinoma and 4% of squamous cell lung cancer. The most common KRAS variant is KRAS G12C, which accounts for nearly 40% of all KRAS mutations. Although it is the most common oncogenic driver in NSCLC, KRAS was considered a "nondruggable target" until recently, owing to the lack of any progress in developing targeted therapies for this oncogene. With the recent development and approva...
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Jyoti Malhotra Danny Nguyen Tingting Tan George B Semeniuk Iii Source Type: research

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research

Management of < em > KRAS < /em > -mutated non-small cell lung cancer
Clin Adv Hematol Oncol. 2024 Mar;22(2):67-75.ABSTRACTKirsten rat sarcoma virus (KRAS) is the most frequently mutated oncogene in human cancers, particularly in non-small cell lung cancer (NSCLC), where mutations are present in 32% of lung adenocarcinoma and 4% of squamous cell lung cancer. The most common KRAS variant is KRAS G12C, which accounts for nearly 40% of all KRAS mutations. Although it is the most common oncogenic driver in NSCLC, KRAS was considered a "nondruggable target" until recently, owing to the lack of any progress in developing targeted therapies for this oncogene. With the recent development and approva...
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Jyoti Malhotra Danny Nguyen Tingting Tan George B Semeniuk Iii Source Type: research

Recombinant interferon alfa in BCR/ABL-negative chronic myeloproliferative neoplasms
This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.PMID:38446475 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Sandy El Bitar Murat O Arcasoy Source Type: research

Epcoritamab, a promising therapy for Richter syndrome?
Clin Adv Hematol Oncol. 2024 Mar;22(2):90-91.NO ABSTRACTPMID:38446476 (Source: Clinical Advances in Hematology and Oncology)
Source: Clinical Advances in Hematology and Oncology - March 6, 2024 Category: Cancer & Oncology Authors: Arnon Kater Source Type: research